KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Minority Interest: 2019-2024

Historic Minority Interest for Royalty Pharma (RPRX) over the last 6 years, with Dec 2024 value amounting to $3.4 billion.

  • Royalty Pharma's Minority Interest fell 5.37% to $3.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 billion, marking a year-over-year decrease of 5.37%. This contributed to the annual value of $3.4 billion for FY2024, which is 4.55% down from last year.
  • As of FY2024, Royalty Pharma's Minority Interest stood at $3.4 billion, which was down 4.55% from $3.6 billion recorded in FY2023.
  • Over the past 5 years, Royalty Pharma's Minority Interest peaked at $5.1 billion during FY2020, and registered a low of $3.4 billion during FY2024.
  • Over the past 3 years, Royalty Pharma's median Minority Interest value was $3.6 billion (recorded in 2023), while the average stood at $3.6 billion.
  • As far as peak fluctuations go, Royalty Pharma's Minority Interest spiked by 14,048.86% in 2020, and later decreased by 12.85% in 2022.
  • Over the past 5 years, Royalty Pharma's Minority Interest (Yearly) stood at $5.1 billion in 2020, then dropped by 11.92% to $4.5 billion in 2021, then declined by 12.85% to $3.9 billion in 2022, then declined by 8.71% to $3.6 billion in 2023, then declined by 4.55% to $3.4 billion in 2024.